1.
Häfliger P, Charles RP. The L-Type Amino Acid Transporter LAT1-An Emerging Target in Cancer. Int
J Mol Sci. May 16 2019;20(10). DOI: 10.3390/ijms20102428
2.
Mishima Y, Kondoh H. Dual control of melanogenesis and melanoma growth: overview molecular
to clinical level and the reverse. Pigment Cell Res. 2000;13 Suppl 8:10-22. DOI: 10.1034/j.16000749.13.s8.6.x
3.
Barth RF, Mi P, Yang W. Boron delivery agents for neutron capture therapy of cancer. Cancer
Commun (Lond). 06 19 2018;38(1):35. DOI: 10.1186/s40880-018-0299-7
4.
Slatkin DN. A history of boron neutron capture therapy of brain tumours. Postulation of a brain
radiation dose tolerance limit. Brain. Aug 1991;114 ( Pt 4):1609-1629.
DOI:
10.1093/brain/114.4.1609
5.
Slatkin DN JM, Joel DD, et al. A History of 20th-Century Boron Neutron-CaptureTherapy. J Neurol
Neurobiol. 2017;3(2). DOI: http://dx.doi.org/10.16966/2379-7150.142
6.
Nakagawa Y, Hatanaka H. Boron neutron capture therapy. Clinical brain tumor studies. J
Neurooncol. May 1997;33(1-2):105-115. DOI: 10.1023/a:1005781517624
7.
Mishima Y, Ichihashi M, Tsuji M, et al. Treatment of malignant melanoma by selective thermal
neutron capture therapy using melanoma-seeking compound. J Invest Dermatol. May 1989;92(5
Suppl):321S-325S. DOI: 10.1111/1523-1747.ep13076750
8.
Henriksson R, Capala J, Michanek A, et al. Boron neutron capture therapy (BNCT) for glioblastoma
multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA).
Radiother Oncol. Aug 2008;88(2):183-191. DOI: 10.1016/j.radonc.2006.04.015
9.
Kankaanranta L, Seppälä T, Koivunoro H, et al. Boron neutron capture therapy in the treatment
of locally recurred head-and-neck cancer: final analysis of a phase I/II trial. Int J Radiat Oncol Biol
Phys. Jan 01 2012;82(1):e67-75. DOI: 10.1016/j.ijrobp.2010.09.057
10.
Menéndez PR, Roth BM, Pereira MD, et al. BNCT for skin melanoma in extremities: updated
Argentine
clinical
results.
Appl
Radiat
Isot.
Jul
2009;67(7-8
Suppl):S50-53.
DOI:
10.1016/j.apradiso.2009.03.020
11.
Wang LW, Chen YW, Ho CY, et al. Fractionated Boron Neutron Capture Therapy in Locally
Recurrent Head and Neck Cancer: A Prospective Phase I/II Trial. Int J Radiat Oncol Biol Phys. May
01 2016;95(1):396-403. DOI: 10.1016/j.ijrobp.2016.02.028
12.
Chen YW LY, Lin CF, et al.,. Salvage Boron Neutron Capture Therapy for Malignant Brain Tumor
Patients in Compliance with Emergency and Compassionate Use: Evaluation of 34 Cases in
Taiwan. . Biology (Basel). 2021;10(4):334. DOI: 10.3390/biology10040334.
13.
Chen YW LY, Lin CF et al. Compassionate Treatment of Brainstem Tumors with Boron Neutron
Capture Therapy: A Case Series. Life (Basel). 2022;12:566. DOI: 10.3390/life12040566.
14.
Miyatake SI, Kawabata S, Hiramatsu R, Kuroiwa T, Suzuki M, Ono K. Boron Neutron Capture
Therapy of Malignant Gliomas. Prog Neurol Surg. 2018;32:48-56. DOI: 10.1159/000469679
15.
Takai S, Wanibuchi M, Kawabata S, et al. Reactor-based boron neutron capture therapy for 44
cases of recurrent and refractory high-grade meningiomas with long-term follow-up. Neuro Oncol.
01 05 2022;24(1):90-98. DOI: 10.1093/neuonc/noab108
16.
Suzuki M, Kato I, Aihara T, et al. Boron neutron capture therapy outcomes for advanced or
recurrent head and neck cancer. J Radiat Res. Jan 01 2014;55(1):146-153. DOI: 10.1093/jrr/rrt098
17.
Hiratsuka J, Kamitani N, Tanaka R, et al. Long-term outcome of cutaneous melanoma patients
treated with boron neutron capture therapy (BNCT). J Radiat Res. Nov 16 2020;61(6):945-951.
DOI: 10.1093/jrr/rraa068
18.
Tanaka H SY, Suzuki M, et al.,. Characteristics comparison between a cyclotron-based neutron
source and KUR-HWNIF for boron neutron capture therapy. Nucl. Instrum. Methods B.
2009;267:1970-1977. doi:10.1016/j.nimb.2009.03.095
19.
Kawabata S, Suzuki M, Hirose K, et al. Accelerator-based BNCT for patients with recurrent
glioblastoma: a multicenter phase II study. Neurooncol Adv. 2021 Jan-Dec 2021;3(1):vdab067.
DOI: 10.1093/noajnl/vdab067
20.
Kanno H, Nagata H, Ishiguro A, et al. Designation Products: Boron Neutron Capture Therapy for
Head and Neck Carcinoma. Oncologist. Jul 2021;26(7):e1250-e1255. DOI: 10.1002/onco.13805
21.
Hirose, K KAHJ, et al. Boron neutron capture therapy using cyclotron-based epithermal neutron
source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): An
open-label
phase
II
trial.
Radiother
Oncol.
2021;155:182-187.
DOI:
https://doi.org/10.1016/j.radonc.2020.11.001
22.
Igaki H, Murakami N, Nakamura S, et al. Scalp angiosarcoma treated with linear accelerator-based
boron neutron capture therapy: A report of two patients. Clin Transl Radiat Oncol. Mar
2022;33:128-133. DOI: 10.1016/j.ctro.2022.02.006
23.
Kiyanagi, Y YY, Kumada H and Tanaka H. Status of accelerator-based BNCT projects worldwide.
AIP Conference Proceedings. Paper presented at: AIP Conference Proceedings., 2019. DOI:
https://doi.org/10.1063/1.5127704
24.
Nuclear Technology Review. 2020:46-48, Austria.
25.
Harling OK, Riley KJ. Fission reactor neutron sources for neutron capture therapy--a critical review.
J Neurooncol. Mar-Apr 2003;62(1-2):7-17. DOI: 10.1007/BF02699930
26.
Kanygin V, Kichigin A, Zaboronok A, et al. In Vivo Accelerator-Based Boron Neutron Capture
Therapy for Spontaneous Tumors in Large Animals: Case Series. Biology (Basel). Jan 14 2022;11(1).
DOI: 10.3390/biology11010138
27.
Masunaga S, Ono K, Sakurai Y, et al. Response of quiescent and total tumor cells in solid tumors
to neutrons with various cadmium ratios. Int J Radiat Oncol Biol Phys. Jul 15 1998;41(5):11631170. DOI: 10.1016/s0360-3016(98)00149-7
28.
Dagrosa MA, Crivello M, Perona M, et al. First evaluation of the biologic effectiveness factors of
boron neutron capture therapy (BNCT) in a human colon carcinoma cell line. Int J Radiat Oncol
Biol Phys. Jan 1 2011;79(1):262-268. DOI: 10.1016/j.ijrobp.2010.07.020
29.
Schwint AE, Monti Hughes A, Garabalino MA, et al. Clinical Veterinary Boron Neutron Capture
Therapy (BNCT) Studies in Dogs with Head and Neck Cancer: Bridging the Gap between
Translational
and
Clinical
Studies.
Biology
(Basel).
Oct
2020;9(10).
DOI:
10.3390/biology9100327
30.
Nakamura S, Imamichi S, Masumoto K, et al. Evaluation of radioactivity in the bodies of mice
induced by neutron exposure from an epi-thermal neutron source of an accelerator-based boron
neutron capture therapy system. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(10):821-831. DOI:
10.2183/pjab.93.051
31.
Protti N, Manera S, Prata M, et al. Gamma residual radioactivity measurements on rats and mice
irradiated in the thermal column of a TRIGA Mark II reactor for BNCT. Health Phys. Dec
2014;107(6):534-541. DOI: 10.1097/HP.0000000000000148
32.
Radiation protection and safety of radiation sources: International basic safety standards, No.
GSR Part 3 IAEA Safety Standards Series (2014).
33.
Ohta T, Iwakawa M, Oohira C, et al. Fractionated irradiation augments inter-strain variation of
skin reactions among three strains of mice. J Radiat Res. Dec 2004;45(4):515-519. DOI:
10.1269/jrr.45.515
34.
Gueulette J, Octave-Prignot M, De Costera BM, Wambersie A, Gregoire V. Intestinal crypt
regeneration in mice: a biological system for quality assurance in non-conventional radiation
therapy. Radiother Oncol. Dec 2004;73 Suppl 2:S148-154. DOI: 10.1016/s0167-8140(04)80038-0
35.
Williams JP, Brown SL, Georges GE, et al. Animal models for medical countermeasures to radiation
exposure. Radiat Res. Apr 2010;173(4):557-578. DOI: 10.1667/RR1880.1
36.
Yamamoto T, Matsumura A, Nakai K, et al. Current clinical results of the Tsukuba BNCT trial. Appl
Radiat Isot. Nov 2004;61(5):1089-1093. DOI: 10.1016/j.apradiso.2004.05.010
37.
Yamamoto T, Nakai K, Kageji T, et al. Boron neutron capture therapy for newly diagnosed
glioblastoma. Radiother Oncol. Apr 2009;91(1):80-84. DOI: 10.1016/j.radonc.2009.02.009
38.
Masuda A, Matsumoto T, Takada K, et al. Neutron spectral fluence measurements using a Bonner
sphere spectrometer in the development of the iBNCT accelerator-based neutron source. Appl
Radiat Isot. Sep 2017;127:47-51. DOI: 10.1016/j.apradiso.2017.05.010
39.
Kumada H, Takada K, Tanaka S, et al. Evaluation of the characteristics of the neutron beam of a
linac-based neutron source for boron neutron capture therapy. Appl Radiat Isot. Nov
2020;165:109246. DOI: 10.1016/j.apradiso.2020.109246
Table 1. Current Status and Performance of Accelerators Intended for BNCT Clinical Trials
Institute
Kyoto
Accelerator type
University,
Target reaction
Cyclotron
Be(p,n)
Beam axis
Horizontal
Beam
Beam
energy
current
(MeV)
(mA)
30
Japan
Present status
Clinical trials for recurrent malignant glioma (MG)(JapicCTI-194742)19 and recurrent and
advanced head and neck (HN) cancer (JHN001)20 and preparing for basic research use
Kansai BNCT
Cyclotron
Be(p,n)
Horizontal
30
Research Center,
Clinical
trial
for
recurrent
MG
(JapicCTI-194742)19
and
Malignant
Meningioma
(jRCT2051190044) and treatments for recurrent and advanced HN cancers
Japan
Southern
Tohoku
Cyclotron
Be(p,n)
Horizontal
30
Hospital, Japan
National
Cancer
(JapicCTI-194640))21, JHN002 Look Up Study) and treatments for HN cancers
Electrodynamic
linear
Li(p,n)
Vertical
2.5
20
Clinical trial for Malignant Melanoma and angiosarcoma (JapicCTI-195062)22
linear
Be(p,n)
Horizontal
10
Preclinical
linear
Be(p,n)
Horizontal
10
Preclinical
Electrostatic accelerator
Li(p,n)
Horizontal
2.6
30
Commissioning
Electrostatic accelerator
Li(p,n)
Horizontal
2.5
10
Commissioning
Center, Tokyo
accelerator
Tsukuba University,
Electrodynamic
Japan
accelerator
Gachon
University
Gil Medical Center,
Clinical trials for MG (JapicCTI-194742)19 and recurrent and advanced HN cancer (JHN002
Electrodynamic
accelerator
South Korea
Helsinki University
Hospital, Finland
Xiamen
Humanity
Hospital, China
Table 2. The facilities of BNCT systems with vertical downward neutron-beam.
Facility
Beam port
Type of BNCT
Main neutron beam
system
Massachusetts Institute of
Downward
Technology Research
vertical &
Reactor (MITR) (USA)
horizontal
CICS-1 in National Cancer
Downward
Center (Japan)
vertical
Novosibirsk State University
Downward
(Ruccisa)
vertical
Reactor
Thermal neutron
AB-BNCT
Epithermal neutron
AB-BNCT
Epithermal neutron
...
論文の公開元へ
